{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:00:09Z","timestamp":1787166009993,"version":"build-2736575974"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint destruction and systemic inflammation, imposing a substantial global health burden, with an estimated 31.7 million cases projected by 2050. Despite advances in therapy, limitations of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologic DMARDs (bDMARDs) persist, including adverse effects, high costs, and inadequate responses in certain patient subgroups. Upadacitinib (UPA), a selective Janus kinase (JAK) 1 inhibitor, represents a breakthrough in targeted synthetic DMARDs (tsDMARDs), offering rapid symptom relief and structural preservation. Clinical trials, including the SELECT-COMPARE study, have demonstrated that UPA outperforms adalimumab in achieving higher 12-week American College of Rheumatology (ACR) 20 (71% vs. 63%), ACR50 (45% vs. 29%), and ACR70 responses, with sustained efficacy extending beyond 5 years. Real-world evidence from the Canadian post-marketing observational CLOSE-UP study corroborated these findings, showing that 63.5% of patients achieved DAS28-CRP \u22642.6\u00a0at 6 months. Compared with pan-JAK inhibitors such as tofacitinib, the JAK1 selectivity of UPA may reduce off-target effects; however, safety concerns remain, including an increased risk of herpes zoster (particularly in Asian populations), liver enzyme abnormalities, and potential cardiovascular events. Cost remains a major barrier, with annual expenses exceeding USD 60,000 for uninsured patients, although partially alleviated by insurance coverage. Future directions highlight combination strategies, personalized treatment approaches, and broader applications in psoriatic arthritis and ankylosing spondylitis. While UPA enhances RA management through its oral convenience and robust efficacy, addressing long-term safety monitoring, affordability, and mechanisms underlying refractory RA remains imperative for optimizing global patient outcomes.<\/jats:p>","DOI":"10.3389\/fphar.2026.1776317","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:36:12Z","timestamp":1773758172000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Upadacitinib in rheumatoid arthritis: progress and challenges"],"prefix":"10.3389","volume":"17","author":[{"given":"Qiaofen","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medicine, Hainan Medical University","place":["Haikou, China"]},{"name":"Department of Rheumatology and Immunology, Hainan Affiliated Hospital of Hainan Medical University (Hainan General Hospital)","place":["Haikou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhong","sequence":"additional","affiliation":[{"name":"Shenzhen University Medical School, Shenzhen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hainan Medical University","place":["Haikou, China"]},{"name":"Department of Rheumatology and Immunology, Hainan Affiliated Hospital of Hainan Medical University (Hainan General Hospital)","place":["Haikou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Hainan Affiliated Hospital of Hainan Medical University (Hainan General Hospital)","place":["Haikou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay4447","article-title":"JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function","volume":"12","author":"Adam","year":"2020","journal-title":"Sci. Translational Medicine"},{"key":"B2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","article-title":"Baricitinib: a review in rheumatoid arthritis","volume":"78","author":"Al-Salama","year":"2018","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.coi.2019.09.004","article-title":"B cell targeted therapies in autoimmune disease","volume":"61","author":"Barnas","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1007\/s12325-021-01930-4","article-title":"Economic benefit from improvements in quality of life with upadacitinib: comparisons with tofacitinib and methotrexate in patients with rheumatoid arthritis","volume":"38","author":"Bergman","year":"2021","journal-title":"Adv. Therapy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40744-024-00651-8","article-title":"Real-world effectiveness of upadacitinib for treatment of rheumatoid arthritis in Canadian patients: interim results from the prospective observational CLOSE-UP study","volume":"11","author":"Bessette","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000493390","article-title":"Rheumatoid arthritis: a brief overview of the treatment","volume":"27","author":"Bullock","year":"2018","journal-title":"Med. Princ. Pract."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s40744-024-00694-x","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis refractory to biologic DMARDs: results through week 216 from the SELECT-CHOICE study","volume":"11","author":"Burmester","year":"2018","journal-title":"Rheumatol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s12325-024-02948-0","article-title":"A real-world comparison of clinical effectiveness in patients with rheumatoid arthritis treated with upadacitinib, tumor necrosis factor inhibitors, and other advanced therapies after switching from an initial tumor necrosis factor inhibitor","volume":"41","author":"Caporali","year":"2024","journal-title":"Adv. Therapy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1093\/rheumatology\/kez002","article-title":"Clinical significance of janus kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.55563\/clinexprheumatol\/n0kjax","article-title":"Real-world utilisation and switching between janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset","volume":"42","author":"Ciciriello","year":"2024","journal-title":"Clin. Experimental Rheumatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann. Rheumatic Diseases"},{"key":"B14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen","year":"2021","journal-title":"Ann. Rheumatic Diseases"},{"key":"B15","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann. Rheumatic Diseases"},{"key":"B16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40264-020-01036-w","article-title":"Upadacitinib in rheumatoid arthritis: a benefit\u2013risk assessment across a phase III Program","volume":"44","author":"Conaghan","year":"2021","journal-title":"Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/rheumatology\/kex349","article-title":"Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need","volume":"57","author":"de Hair","year":"2018","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT\u2010AXIS 2): a randomised, double\u2010blind, placebo\u2010controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: a review in rheumatoid arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-020-01439-0","article-title":"Filgotinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40744-021-00405-w","article-title":"Frequency and duration of early non-serious adverse events in patients with rheumatoid arthritis and psoriatic arthritis treated with tofacitinib","volume":"9","author":"Dikranian","year":"2022","journal-title":"Rheumatology Therapy"},{"key":"B22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40744-020-00257-w","article-title":"A matching-adjusted indirect comparison of upadacitinib versus tofacitinib in adults with moderate-to-severe rheumatoid arthritis","volume":"8","author":"Edwards","year":"2021","journal-title":"Rheumatology Therapy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis and Rheumatology (Hoboken, NJ)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e002012","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e004007","DOI":"10.1136\/rmdopen-2023-004007","article-title":"Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study","volume":"10","author":"Fleischmann","year":"2024","journal-title":"RMD Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","article-title":"Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British society for rheumatology Biologics register with special emphasis on risks in the elderly","volume":"50","author":"Galloway","year":"2010","journal-title":"Rheumatol. (Oxford)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17938","article-title":"Cardiovascular risk associated with TNF alpha inhibitor use in patients with rheumatoid arthritis","volume":"13","author":"Hussain","year":"2021","journal-title":"Cureus"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1172\/JCI78089","article-title":"T cells in the control of organ-specific autoimmunity","volume":"125","author":"Jeffrey","year":"2015","journal-title":"J. Clin. Invest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann. Rheumatic Diseases"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study","volume":"393","author":"Josef","year":"2025","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-020-02387-6","article-title":"Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)","volume":"23","author":"Kameda","year":"2021","journal-title":"Arthritis Res. and Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.3390\/ijms25158327","article-title":"JAK inhibitors in rheumatoid arthritis: immunomodulatory properties and clinical efficacy","volume":"25","author":"Kie\u0142bowski","year":"2024","journal-title":"Int. Journal Molecular Sciences"},{"key":"B39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1159\/000527186","article-title":"Relative remission and low disease activity rates of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate in patients with disease-modifying antirheumatic drug-naive rheumatoid arthritis","volume":"108","author":"Lee","year":"2023","journal-title":"Pharmacology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"JAKS AND STATS: biological implications*","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf097","article-title":"Cost-utility analysis of upadacitinib versus dupilumab for atopic dermatitis in Australia","author":"Li","year":"2025","journal-title":"Clin. Exp. Dermatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M17-1176","article-title":"Improvement at any cost? The art and science of choosing treatment strategies for rheumatoid arthritis","volume":"167","author":"Losina","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40264-024-01454-0","article-title":"Pregnancy outcomes in patients treated with upadacitinib: analysis of data from clinical trials and postmarketing reports","volume":"47","author":"Mahadevan","year":"2024","journal-title":"Drug Safety"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1172\/JCI78086","article-title":"Genetic basis of autoimmunity","volume":"125","author":"Marson","year":"2015","journal-title":"J. Clin. Investigation"},{"key":"B46","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","article-title":"Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis","volume":"22","author":"Mattay","year":"2024","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. Journal Medicine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N. Engl. Journal Medicine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e13688","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin. Translational Science"},{"key":"B50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2020","journal-title":"Ann. Rheumatic Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13075-017-1309-x","article-title":"Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis","volume":"19","author":"Nakachi","year":"2017","journal-title":"Arthritis Res. and Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurevmed-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu. Review Medicine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/ibd\/izaa318","article-title":"Clinical and mechanistic characteristics of current JAK inhibitors in IBD","volume":"27","author":"Pippis","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N. Engl. Journal Medicine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Reviews Gastroenterology and Hepatology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/jcm12051734","article-title":"Upadacitinib for patients with rheumatoid arthritis: a comprehensive review","volume":"12","author":"Sanmart\u00ed","year":"2023","journal-title":"J. Clinical Medicine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"152314","DOI":"10.1016\/j.semarthrit.2023.152314","article-title":"Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: australia wide study","volume":"64","author":"Scheepers","year":"2024","journal-title":"Seminars Arthritis Rheumatism"},{"key":"B61","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Reviews Drug Discovery"},{"key":"B62","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of Follow-up data from the measure up 1 and measure up 2 randomized clinical trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care and Research"},{"key":"B64","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheumatic Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(16)30794-2","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet London, Engl."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet London, Engl."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheumatic Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00393-020-00889-x","article-title":"Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-na\u00efve patients with rheumatoid arthritis","volume":"80","author":"Sung","year":"2021","journal-title":"Z. fur Rheumatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"T Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"B71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/ph15010030","article-title":"Molecular modeling insights into upadacitinib selectivity upon binding to JAK protein family","volume":"15","author":"Taldaev","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B72","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. Journal Medicine"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"","journal-title":"Lancet London, Engl."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e000898","DOI":"10.1136\/rmdopen-2019-000898","article-title":"Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis","volume":"5","author":"van der Heijde","year":"","journal-title":"RMD Open"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"van der Heijde","year":"2022","journal-title":"Ann. Rheumatic Diseases"},{"key":"B76","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13075-024-03358-x","article-title":"Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial","volume":"26","author":"van Vollenhoven","year":"2024","journal-title":"Arthritis Research and Therapy"},{"key":"B77","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review","volume":"10","author":"Wang","year":"2018","journal-title":"Eur. Journal Medicinal Chemistry"},{"key":"B78","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","article-title":"Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann. Rheumatic Diseases"},{"key":"B79","doi-asserted-by":"publisher","first-page":"726","DOI":"10.55563\/clinexprheumatol\/11255h","article-title":"The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study","volume":"42","author":"Witte","year":"2024","journal-title":"Clin. Experimental Rheumatology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/1750743X.2024.2426972","article-title":"Cost-effectiveness of upadacitinib vs. tofacitinib for moderate-to-severe rheumatoid arthritis in China","volume":"16","author":"Xu","year":"2024","journal-title":"Immunotherapy"},{"key":"B81","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","article-title":"JAK inhibitors: prospects in connective tissue diseases","volume":"59","author":"You","year":"2020","journal-title":"Clin. Reviews Allergy and Immunology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40744-024-00736-4","article-title":"Real-world persistence and effectiveness of upadacitinib versus other janus kinase inhibitors and tumor necrosis factor inhibitors in Australian patients with rheumatoid arthritis","volume":"12","author":"Youssef","year":"2025","journal-title":"Rheumatology Therapy"},{"key":"B83","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. Journal Medicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1776317\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:36:13Z","timestamp":1773758173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1776317\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":83,"alternative-id":["10.3389\/fphar.2026.1776317"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1776317","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"article-number":"1776317"}}